LOS ANGELES--(BUSINESS WIRE)--Kythera Biopharmaceuticals, Inc. (“Kythera”) announced today that it has initiated a Phase II study of its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This is the first in a series of planned studies of ATX-101 in aesthetic applications aimed at proving the product’s safety and effectiveness as a “liposculpting” agent.
